Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 16/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17819329 | 0.91 | ELANE (0.50) | ELANECYP3A4CTSKMEN1KMT2A | |
| SCHEMBL17819304 | 0.89 | ELANE (0.62) | ELANECYP3A4CTSKMEN1KMT2A | |
| SCHEMBL21828992 | 0.88 | ELANE (0.47) | ELANECYP3A4CTSKMEN1KMT2A | |
| SCHEMBL17819289 | 0.87 | ELANE (0.47) | ELANECYP3A4CTSK | |
| SCHEMBL17819345 | 0.83 | ELANE (0.64) | ELANECYP3A4CTSKMEN1KMT2A | |
| SCHEMBL19677885 | 0.82 | ELANE (0.61) | ELANECYP3A4CTSKMEN1KMT2A | |
| SCHEMBL15841229 | 0.81 | ELANE (0.51) | ELANECYP3A4CTSKMEN1KMT2A | |
| SCHEMBL17819299 | 0.81 | ELANE (0.62) | ELANECYP3A4CTSKMEN1KMT2A | |
| SCHEMBL17819301 | 0.80 | ELANE (0.59) | ELANECYP3A4CTSKMEN1KMT2A | |
| Benzene SCHEMBL19639783 | 0.80 | ELANE (0.47) | ELANECYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168101-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168101-A1 | NOVEL COMPOUNDS | ELANE, SERPINB1, MPO | ELANE 1/4885CYP3A4 1182/4885CTSK 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.